Dan Goldstein's Insider Trades & SAST Disclosures
Dan Goldstein's most recent trade in Pitney Bowes, Inc. was a trade of 7,892 Restricted Stock Units done . Disclosure was reported to the exchange on March 12, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Dan Goldstein.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Corp Sec. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2024 | 7,892 | 0 | - | - | Restricted Stock Units | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Corp Sec. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2024 | 7,892 | 101,054 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Corp Sec. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.09 per share. | 12 Mar 2024 | 3,561 | 97,493 (0%) | 0% | 4.1 | 14,547 | Common Stock |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 1,260 | 89,817 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 1,260 | 112,895 | - | - | Restricted Stock Units | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 07 Mar 2024 | 1,260 | 88,557 (0%) | 0% | 3.9 | 4,883 | Common Stock |
| Pitney Bowes, Inc. | Goldstein Daniel | EVP/Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 125,313 | 364,754 | - | - | Restricted Stock Units | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 7,891 | 91,031 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 7,891 | 14,134 | - | - | Restricted Stock Units | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 14 Mar 2023 | 2,474 | 88,557 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 1,364 | 20,661 | - | - | Restricted Stock Units | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 1,364 | 82,185 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.26 per share. | 21 Feb 2023 | 1,364 | 80,821 (0%) | 0% | 4.3 | 5,807 | Common Stock |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 114,155 | 238,595 | - | - | Restricted Stock Units | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Purchase of securities on an exchange or from another person at price $ 3.32 per share. | 29 Jul 2022 | 3,013 | 80,821 (0%) | 0% | 3.3 | 10,000 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 62.60 per share. | 13 Jun 2022 | 42 | 4,447 (0%) | 0% | 62.6 | 2,629 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 62.69 per share. | 02 Jun 2022 | 249 | 4,489 (0%) | 0% | 62.7 | 15,610 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 59.10 per share. | 19 May 2022 | 134 | 4,738 (0%) | 0% | 59.1 | 7,919 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 2,029 | 2,029 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 868 | 4,872 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 56.10 per share. | 16 May 2022 | 50 | 4,004 (0%) | 0% | 56.1 | 2,805 | Common Stock |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2022 | 7,892 | 14,133 | - | - | Restricted Stock Units | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2022 | 7,892 | 78,814 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 08 Mar 2022 | 2,474 | 76,340 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 101,833 | 225,886 | - | - | Restricted Stock Units | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 3,352 | 69,360 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 3,352 | 18,673 | - | - | Restricted Stock Units | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.91 per share. | 11 Feb 2022 | 3,352 | 66,008 (0%) | 0% | 4.9 | 16,458 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 59.87 per share. | 14 Jun 2021 | 39 | 4,054 (0%) | 0% | 59.9 | 2,335 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 55.09 per share. | 07 Jun 2021 | 81 | 4,093 (0%) | 0% | 55.1 | 4,462 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 1,753 | 4,174 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 2,690 | 2,690 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 994 | 2,463 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 55.19 per share. | 18 May 2021 | 42 | 2,421 (0%) | 0% | 55.2 | 2,318 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 55.98 per share. | 17 May 2021 | 42 | 1,469 (0%) | 0% | 56.0 | 2,351 | Common Stock |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 45,259 | 439,010 | - | - | Stock Option | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 23,675 | 124,943 | - | - | Restricted Stock Units | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 1,860 | 67,868 (0%) | 0% | 0 | Common Stock | |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.33 per share. | 16 Feb 2021 | 1,860 | 66,008 (0%) | 0% | 9.3 | 17,354 | Common Stock |
| Pitney Bowes, Inc. | Daniel Goldstein | EVP/Chief Legal & Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 1,860 | 20,165 | - | - | Restricted Stock Units | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.21 per share. | 04 Feb 2021 | 1,457 | 3,206 (0%) | 0% | 34.2 | 49,844 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 1,457 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 135.84 per share. | 04 Feb 2021 | 1,457 | 1,749 (0%) | 0% | 135.8 | 197,919 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 500 | 1,503 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 135.72 per share. | 04 Feb 2021 | 500 | 1,749 (0%) | 0% | 135.7 | 67,860 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 98.03 per share. | 04 Feb 2021 | 500 | 2,249 (0%) | 0% | 98.0 | 49,013 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 476 | 952 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 135.88 per share. | 04 Feb 2021 | 476 | 1,749 (0%) | 0% | 135.9 | 64,679 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 93.52 per share. | 04 Feb 2021 | 476 | 2,225 (0%) | 0% | 93.5 | 44,516 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 136.26 per share. | 04 Feb 2021 | 238 | 1,511 (0%) | 0% | 136.3 | 32,430 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 106.00 per share. | 26 Oct 2020 | 100 | 1,749 (0%) | 0% | 106 | 10,600 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2020 | 4,322 | 6,305 (0%) | 0% | 0 | Common Stock | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 91.53 per share. | 12 Jun 2020 | 3,040 | 1,849 (0%) | 0% | 91.5 | 278,251 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 87.71 per share. | 12 Jun 2020 | 1,282 | 4,889 (0%) | 0% | 87.7 | 112,444 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 87.16 per share. | 12 Jun 2020 | 92 | 6,171 (0%) | 0% | 87.2 | 8,019 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 82.29 per share. | 12 Jun 2020 | 42 | 6,263 (0%) | 0% | 82.3 | 3,456 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2020 | 1,106 | 1,107 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.64 per share. | 08 Jun 2020 | 1,106 | 3,276 (0%) | 0% | 41.6 | 46,054 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 99.09 per share. | 08 Jun 2020 | 1,106 | 2,170 (0%) | 0% | 99.1 | 109,594 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 97.19 per share. | 08 Jun 2020 | 187 | 1,983 (0%) | 0% | 97.2 | 18,175 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 97.02 per share. | 08 Jun 2020 | 83 | 2,170 (0%) | 0% | 97.0 | 8,053 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 1,841 | 1,841 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 544 | 2,253 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 101.72 per share. | 15 May 2020 | 101 | 1,709 (0%) | 0% | 101.7 | 10,274 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 100.43 per share. | 15 May 2020 | 42 | 1,810 (0%) | 0% | 100.4 | 4,218 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.42 per share. | 06 Apr 2020 | 2,607 | 5,059 (0%) | 0% | 34.4 | 89,733 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2020 | 2,607 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 101.62 per share. | 06 Apr 2020 | 2,607 | 2,452 (0%) | 0% | 101.6 | 264,923 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 97.12 per share. | 06 Apr 2020 | 399 | 1,852 (0%) | 0% | 97.1 | 38,751 | Common Stock |
| Haemonetics Corp. | Dan Goldstein | VP, Corporate Controller | Sale of securities on an exchange or to another person at price $ 103.91 per share. | 06 Apr 2020 | 201 | 2,251 (0%) | 0% | 103.9 | 20,886 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges